Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

The state-run <keyword id="6355033" type="UNKNOWN" weightage="20" keywordseo="bangalore">Bangalore</keyword> <keyword id="6356415" type="UNKNOWN" weightage="20" keywordseo="Metro">Metro</keyword> Rail Corporation Ltd (BMRCL) is ready to resume its services in the tech city amid Covid pandemic, an official said on Wednesday. "We are waiting for the Central government's clearance to resume operations on east-west and north-south routes in compliance with the standard operating procedures (SOPs) of the Union Ministry of Home Affairs and guidelines of the Union Health Ministry to ensure the safety of commuters," the official told IANS. Like other state-run transport firms, Namma Metro too suspended its services since March 25, when the lockdown was suddenly enforced and extended, forcing thousands of commuters to switch over to alternative modes of transport. "Though limited bus, train and plane services were allowed to resume gradually during the three-phases of unlocking, regular express/mail passenger trains and metro rail services remained suspended to prevent crowding in public places and the virus spread," said the official. As the most popular transport mode for its punctual, efficient and cleaner service in air-conditioned coaches, the metro has been ferrying more than four lakh commuters on the twin routes, covering 42.3 km across 44 well-lit stations till pre-Covid days. "As social distancing has to be maintained, the guidelines may limit the number of commuters to one-third of the capacity in a six-coach train, that in normal times carries nearly 1,000 people per trip," the official observed. To ensure the commuters are virus-free, they will be screened at the entrance and advised to keep wearing mask throughout the journey for their safety and that of others. "As most of the commuters use smartphones, they will be advised to download the 'Aarogya Setu' application (app) for contact tracing in the event of any of them getting infected by the virus," the official added. All commuters will be advised to use e-tickets in the form of a smart card for entry and exit from the metro stations to minimise contact with tokens. "We are hoping the government to permit resuming <keyword id="63449" type="ORGANIZATION" weightage="20" keywordseo="Metro-services">metro services</keyword> in a phased manner under the guidelines to ensure the safety of commuters and the staff as restrictions on inter-state and intra-state travel have been lifted across the country," the official said. As a joint venture between the state and Centre, the operator has incurred Rs 300 crore loss over the last five months due to the suspension of its services to contain the pandemic.

Bengaluru is ready to resume metro services but needs clearance from central government

<ul><li><keyword id="9525515" type="UNKNOWN" weightage="20" keywordseo="Globe-Biotech">Globe Biotech</keyword> Limited has claimed to be the first company from Bangladesh to have a <keyword id="8904563" type="UNKNOWN" weightage="20" keywordseo="covid-19-vaccine">Covid-19 vaccine</keyword> under development. </li><li>It says it is aiming for a December 2020 availability of the vaccine in the market.</li><li>They received the result after conducting the preliminary trial on five rabbits from June 10 to June 28, says Dr Asif Mahmud, Assistant Manager and incharge of Research and Development, Globe Biotech Limited, in an exclusive interview to IANS.</li></ul> Claiming success in preliminary animal modelling trial of Covid-19 vaccine, Globe Biotech Limited has claimed to be the first company from Bangladesh to have a Covid-19 vaccine under development. It says it is aiming for a December 2020 availability of the vaccine in the market. They received the result after conducting the preliminary trial on five rabbits from June 10 to June 28, says Dr Asif Mahmud, Assistant Manager and incharge of Research and Development, Globe Biotech Limited, in an exclusive interview to IANS. Earlier, he led the team to claim success in preliminary trial for the vaccine in national capital Dhaka on Thursday afternoon. Excerpts from the interview of scientist Dr Asif Mahmud Q: Globe Biotech is a research company in Bangladesh. Is it a branch of any MNC in the world? A: No, in fact, Globe Biotech Limited is a Biological Drug Discovery Company in operation in Bangladesh since 2015. The project was started by our CEO Kankon Nag and COO Dr Nazneen Sultana. We have prepared 18 bio similar. We are also working on our own Nobel drug. After completing the animal trials of 6 bio similar, we have applied for Ethical Approval through our PRO at the Bangladesh Medical Research Council (BMRC) in Dhaka. We have that ability and experience to invent a vaccine against this pandemic. Under the supervision of our CEO and COO, after a Covid-19 patient was reported in Bangladesh on March 8, we shifted our focus to SARS-Cov2 and started 3 new projects. Number one -- we will do kit development; number two -- we will do vaccine development for the country; and in the last -- the biological molecule development. Q: Is the research by Globe Biotech independent? Or is your research done under the supervision of any other country? A: Globe Biotech is researching independently. Under the supervision of our CEO and COO, both of whom supervised the team from Canada. They are experienced in this matter. Dr Kankon was directly involved in the HIV vaccine project. He is using that experience here. We are conducting research under their direct supervision. A 12-member scientific group started research on March 18 under the leadership of both. We have taken some 76 genome sequences under consideration, wherein we found that a sequence (numbered 614) has a mutation point that they have used for amino acid bonding. Q: Which method did you follow for the research you are undertaking? And how do you make sure it will work to protect people from Covid-19? A: We went for the SPR method for the tests. Surface plasmon resonance (SPR) is a phenomenon where electrons in the metal surface layer are excited by photons of incident light with a certain angle of incidence, and then propagated parallel to the metal surface. It is an optical technique utilised for detecting molecular interactions. Actually, we have set a vaccine target. We have analysed the sequences from all the databases we have worldwide, including the sequences in Bangladesh. We set the target by our analysis. We have modified that target according to our needs. We have set multiple targets. We have placed multiple delivery systems in consideration. By applying the delivery system we have done an animal trial on rabbits. By this we have got a very good antibody titer. And those antibodies have shown strong binding affinity with our antigen. We have additional candidates, some of which we have presented to the press. But the company is yet to apply for a patent or any publication; and before the patent is ensured it would not disclose the data received from the trial. We have said that we need to convert the data from the preliminary animal trial into a regulated animal trial. That we will do within the next 6 to 8 weeks. Then we will apply for Ethical Approval. Q: This 6 to 8 weeks period, to get proof of animal trial? Or, for trial on humans? A: No, we have already got proof of antibody generation in the preliminary animal trial. Now, it needs to be converted to a regulated animal trial. Because, for human trial, we have to submit it to the regulatory body for Ethical Approval. Regulated trials will require some further characterisation. Then, we will apply for human trials. Q: Did you inform about your research to the drug administration of the country? A: Not yet. There is no role of the regulatory body now. When we do a regulated animal trial, of course, we go to the regulatory body. Q: What are your expectations? When will the vaccine be released? A: We have already formulated the regulated animal trial guidelines and the tests would be concluded within four to six weeks. Thereafter, the company will seek Ethical Approval from the Bangladesh Medical Research Council (BMRC) in early September, when the data from the Regulated Animal Trial reaches us within 6 to 7 weeks. And then, we will apply for market authorisation to the regulatory authority in December within three months after completing the phases 1, 2 and 3. If everything goes smoothly, we expect to be able to bring our vaccine to the market by December. Q: If you get government support, do you think success for you can be faster or smoother? A: Obviously! This will be the first discovery of this vaccine in Bangladesh. The first task always comes with more obstacles and hindrances. We will remove the obstacles with the support of the government and will bring the vaccine to the market in due course. SEE ALSO: <a href="https://www.businessinsider.in/international/news/india-just-surpassed-russia-to-become-the-country-with-the-3rd-highest-number-of-coronavirus-infections/articleshow/76804658.cms">India just surpassed Russia to become the country with the 3rd-highest number of coronavirus infections</a> <a href="https://www.businessinsider.in/tech/news/india-vice-president-launches-a-social-media-super-app-elyments-which-will-take-on-facebook-instagram-and-whatsapp/articleshow/76796178.cms">India’s Vice President launches a social media super app Elyments, which will take on Facebook, Instagram and WhatsApp</a> <a href="https://www.businessinsider.in/tech/news/intel-will-speed-up-mukesh-ambanis-5g-run-power-him-with-ai-and-possibly-a-jio-laptop/articleshow/76780290.cms">Intel will speed up Mukesh Ambani’s 5G run, power him with AI and possibly a Jio laptop⁠— all in return for massive amount of data</a>

Bangladesh might have Covid-19 vaccine by December, says Globe Biotech scientist

You Searched For "BMRC" and got 2 results

Bengaluru is ready to resume metro services but needs clearance from central government

IANS

Bangladesh might have Covid-19 vaccine by December, says Globe Biotech scientist

IANS

Popular Keywords

Buying Guides